SEL Respiratory Outcomes and Monitoring Framework measures for uncontrolled COPD with raised eosinophils

June 2026 to March 2027

KPI	Intervention	Target	Measure and frequency	Data Source	Who Measures	Frequency of reporting (in any financial year)
1	Audit of patients initiated on dupilumab	100% of all patients initiated on dupilumab to meet NICE criteria at baseline as outlined in the pathway	Snapshot audit to demonstrate: % of patients initiated on dupilumab for COPD who meet all three NICE criteria for initiation* (In the event of less than 100% adherence, exceptions will be reviewed and cohort in SEL v non-SEL reported) *Reasons for deviations in initiation/use of treatment outside of eligibility criteria according to pathway to be outlined. The NICE criteria for initiation of dupilumab are: a. Established on triple therapy inhaler (LABA/LAMA/ICS) or LABA/LAMA inhaler if ICS is not appropriate **and** b. Has uncontrolled COPD defined as ≥ 1 severe or ≥ 2 moderate exacerbations in the last 12 months **and** c. Raised blood eosinophils defined as having a count of ≥ 0.3 x 10^9 cells (300 cells/μL)	Trust Database	Trust	6 monthly starting in September 2026
2	Review of all patients on dupilumab for COPD	100% of patients on dupilumab for COPD are reviewed at 12 months to assess response	Snapshot audit to demonstrate: a) % of patients under the care of the secondary care on dupilumab who have been reviewed at 12 months to assess response	Trust Database	Trust	Annual. To start in June 2027

Approval date: July 2026 **Review date:** April 2027 **(or sooner if evidence or practice changes)**

			b) Number of patients who have achieved adequate response and continue on treatment in line with NICE criteria as outlined in the pathway c) Number of patients who have stopped treatment (and broad themes on reasons) The NICE criteria for stopping dupilumab are: Stop dupilumab if, compared with the 12 months before starting it: • the number of severe exacerbations is the same or higher **or** • the number of moderate exacerbations is higher			
3	Measure impact of the pathway on overall service commissioning costs to ensure value for money	High cost drugs use (Dupilumab) in SEL	Breakdown of dupilumab use for COPD and cost for SEL ICB	Acute activity	SEL ICB (Business Intelligence & Trust High Cost Drug reporting)	Review of data at Responsible Respiratory Prescribing Group starting in September 2026

Approved by:

- SEL Responsible Respiratory Prescribing Group: July 2026
- SEL Integrated Medicines Optimisation Committee: July 2026
- Review date: April 2027